Compare Huntington Ingalls Industries Inc (HII) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Huntington Ingalls Industries Inc trades at $265.15 (market cap $10.16B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Huntington Ingalls Industries Inc is far larger — about 2.1× Travere Therapeutics Inc. Common Stock's market cap, and Huntington Ingalls Industries Inc pays a 2.14% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 30 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| HII | TVTX | |
|---|---|---|
Market Cap | $10.16B | $4.88B |
Volume | 503,029 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $453.73 | $67.52 |
52-Week Low | $257.05 | $26.79 |
Typical Hold Time | 30 Days | 0 Days |
Enterprise Value | $13.08B | $5.01B |
Dividend Yield | 2.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $257.84, down 2.34% today, amid a bearish technical signal but strong fundamentals. The company demonstrates consistent earnings beats, with Q2 2026 EPS of $5.27 exceeding expectations by 39%. Recent contract wins, including a $5.1 billion aircraft carrier overhaul and 10 unmanned vessel orders, bolster its $57.3 billion backlog. Valuation metrics appear attractive with a P/E of 15.36 and P/S of 0.77.
The investment case balances strong defense sector positioning against near-term technical weakness. Analyst consensus targets $357.00, implying 38% upside, with 41% buy ratings. Key risks include execution on large contracts and defense budget fluctuations. The current price near support at $258 presents a potential entry point for long-term investors.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
